Recent Research Analysts’ Ratings Updates for TherapeuticsMD (TXMD)

Several analysts have recently updated their ratings and price targets for TherapeuticsMD (NASDAQ: TXMD):

• 11/9/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/3/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/28/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/22/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/16/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/10/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/4/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/28/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/22/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/16/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

TherapeuticsMD Price Performance

TherapeuticsMD stock opened at $1.52 on Monday. The business’s 50-day moving average price is $1.64 and its 200 day moving average price is $1.79. TherapeuticsMD, Inc. has a 52 week low of $1.43 and a 52 week high of $3.07.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The business had revenue of $0.23 million during the quarter.

Institutional Trading of TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP grew its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the period. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. 30.74% of the stock is owned by institutional investors and hedge funds.

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.